Intervacc reports low infection rate following Strangvac rollout

Intervacc AB has reported that after 100,000 doses of its vaccine Strangvac were administered in the European Union and the United Kingdom, only three confirmed cases of Streptococcus equi were documented in horses that had completed their primary vaccination series. This data suggests a high efficacy rate for the product in field conditions.

Strangles, caused by Streptococcus equi, remains the most frequently diagnosed infectious disease in horses globally. The bacterial infection is characterized by its high contagion rate, spreading easily through direct contact between animals or via contaminated surfaces and equipment.

Vaccination serves as a primary control measure against the disease, which can be lethal in equine populations. The reported figures provide real-world insights into the vaccine's performance outside of controlled clinical trials, marking a significant milestone for Intervacc as it monitors the product's impact on disease transmission patterns.